BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and dialysability of warfarin in end-stage renal disease. 1993

O Ifudu, and A L Dulin

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin

Related Publications

O Ifudu, and A L Dulin
Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis.
August 2014, Investigative radiology,
O Ifudu, and A L Dulin
Warfarin Use and Increased Mortality in End-Stage Renal Disease.
January 2017, American journal of nephrology,
O Ifudu, and A L Dulin
Alprazolam in end-stage renal disease: I. Pharmacokinetics.
June 1991, Journal of clinical pharmacology,
O Ifudu, and A L Dulin
Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.
January 1988, Clinical pharmacology and therapeutics,
O Ifudu, and A L Dulin
Nefopam pharmacokinetics in patients with end-stage renal disease.
November 2010, Anesthesia and analgesia,
O Ifudu, and A L Dulin
End-Stage Renal Disease, Nonvalvular Atrial Fibrillation, and the Warfarin Dilemma.
June 2020, Mayo Clinic proceedings,
O Ifudu, and A L Dulin
Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.
January 2002, The Journal of international medical research,
O Ifudu, and A L Dulin
The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.
February 2001, Pharmacotherapy,
O Ifudu, and A L Dulin
Pharmacokinetics of torasemide and its metabolites in end-stage renal disease.
January 1994, European journal of clinical pharmacology,
O Ifudu, and A L Dulin
Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis.
August 1992, AIDS (London, England),
Copied contents to your clipboard!